沃森生物(300142.SZ):20價肺炎球菌多糖結合疫苗臨牀研究申請獲得受理
格隆匯1月21日丨沃森生物(300142.SZ)公佈,公司及子公司玉溪沃森生物技術有限公司和雲南疫苗實驗室有限公司聯合研發的20價肺炎球菌多糖結合疫苗向國家藥品監督管理局申請臨牀試驗,並於近日獲得《受理通知書》。
20價肺炎球菌多糖結合疫苗(PCV20)為公司自主研發,是在公司已生產上市的13價肺炎球菌多糖結合疫苗基礎上研發的升級產品,覆蓋更多的肺炎球菌致病血清型。接種本疫苗後可刺激機體產生免疫力,用於預防由本疫苗包含的20種血清型肺炎球菌引起的感染性疾病。目前,國內肺炎結合疫苗市場主要以13價肺炎球菌多糖結合疫苗為主,尚無20價肺炎球菌多糖結合疫苗批准上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.